Eris Lifesciences Limited

INR 34,000

IN MARKET RANK FROM #29 to #21 From FY 17 to FY 23 FY 17 • Market Rank #29 • Covered Market ~ INR 34,000 cr Sources of Capital • Operating Cashflow ~ INR 2,100 cr. + • External funding at competitiv

INR 2,100

• Market Rank #29 • Covered Market ~ INR 34,000 cr Sources of Capital • Operating Cashflow ~ INR 2,100 cr. + • External funding at competitive rates Capital Deployment • Invested in inorganic growth

INR 1,860

+ • External funding at competitive rates Capital Deployment • Invested in inorganic growth ~ INR 1,860 cr. • Capex ~ INR 400 cr. • Dividend/ Buyback ~ INR 400 cr. FY 23 • Market Rank #21 • Covered M

INR 400

competitive rates Capital Deployment • Invested in inorganic growth ~ INR 1,860 cr. • Capex ~ INR 400 cr. • Dividend/ Buyback ~ INR 400 cr. FY 23 • Market Rank #21 • Covered Market ~ INR 90,000 cr

INR 90,000

ex ~ INR 400 cr. • Dividend/ Buyback ~ INR 400 cr. FY 23 • Market Rank #21 • Covered Market ~ INR 90,000 cr • Balanced Capital Deployment Strategy deploying internal accruals with external funding to driv

3.5%

g internal accruals with external funding to drive growth • Expanded market share in Diabetes from 3.5% to 5% and in VMN from 1% to 2.5% • Successfully diversified into new therapies – Dermatology, CNS,

5%

al accruals with external funding to drive growth • Expanded market share in Diabetes from 3.5% to 5% and in VMN from 1% to 2.5% • Successfully diversified into new therapies – Dermatology, CNS, Women

1%

ternal funding to drive growth • Expanded market share in Diabetes from 3.5% to 5% and in VMN from 1% to 2.5% • Successfully diversified into new therapies – Dermatology, CNS, Women’s Health, Nephrolo

2.5%

funding to drive growth • Expanded market share in Diabetes from 3.5% to 5% and in VMN from 1% to 2.5% • Successfully diversified into new therapies – Dermatology, CNS, Women’s Health, Nephrology and I

80%

ology and Insulins • Fundamental strength of business model intact – 6-year average Gross Margin > 80%, EBITDA % > 35%, OCF as % of EBITDA > 75% 2 EMERGING THERAPIES NOW ACCOUNT FOR ~ 30% OF REVE

35%

ns • Fundamental strength of business model intact – 6-year average Gross Margin > 80%, EBITDA % > 35%, OCF as % of EBITDA > 75% 2 EMERGING THERAPIES NOW ACCOUNT FOR ~ 30% OF REVENUE Therapy-wis

75%

f business model intact – 6-year average Gross Margin > 80%, EBITDA % > 35%, OCF as % of EBITDA > 75% 2 EMERGING THERAPIES NOW ACCOUNT FOR ~ 30% OF REVENUE Therapy-wise composition of revenue – M